{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:48:08Z","timestamp":1784155688809,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Beyond their success in cardiovascular disease prevention, statins are increasingly recognized to have sex-specific pleiotropic effects. To gain additional insight, we characterized associations of genetically mimicked statins across the phenotype sex-specifically. We also assessed whether any apparently non-lipid effects identified extended to genetically mimicking other widely used lipid modifiers (proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and ezetimibe) or were a consequence of low-density lipoprotein cholesterol (LDL-c).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a sex-specific phenome-wide association study assessing the association of genetic variants in <jats:italic>HMGCR<\/jats:italic>, mimicking statins, with 1701 phenotypes. We used Mendelian randomization (MR) to assess if any non-lipid effects found were evident for genetically mimicked PCSK9 inhibitors and ezetimibe or for LDL-c.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>As expected, genetically mimicking statins was inversely associated with LDL-c, apolipoprotein B (ApoB), and total cholesterol (TC) and positively associated with glycated hemoglobin (HbA1c) and was related to body composition. Genetically mimicking statins was also inversely associated with serum calcium, sex hormone-binding globulin (SHBG), and platelet count and positively associated with basal metabolic rate (BMR) and mean platelet volume. Stronger associations with genetically mimicked statins were evident for women than men for lipid traits (LDL-c, ApoB, and TC), calcium, and SHBG, but not for platelet attributes, body composition, or BMR. Genetically mimicking PCSK9 inhibitors or ezetimibe was also associated with lower lipids, but was not related to calcium, SHBG, BMR, or body composition. Genetically higher LDL-c increased lipids and decreased BMR, but did not affect calcium, HbA1c, platelet attributes, or SHBG with minor effects on body composition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Similar inverse associations were found for genetically mimicking statins on lipid traits in men and women as for other lipid modifiers. Besides the positive associations with HbA1c, BMI (which may explain the higher BMR), and aspects of body composition in men and women, genetically mimicking statins was additionally associated with platelet attributes in both sexes and was inversely associated with serum calcium and SHBG in women. This genetic evidence suggests potential pathways that contribute to the effects of statins particularly in women. Further investigation is needed to confirm these findings and their implications for clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-021-02013-5","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T01:03:02Z","timestamp":1625014982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A phenome-wide association study of genetically mimicked statins"],"prefix":"10.1186","volume":"19","author":[{"given":"Shun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9933-5887","authenticated-orcid":false,"given":"C. M.","family":"Schooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"16","key":"2013_CR1","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMra1806939","volume":"381","author":"ED Michos","year":"2019","unstructured":"Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381(16):1557\u201367. https:\/\/doi.org\/10.1056\/NEJMra1806939.","journal-title":"N Engl J Med"},{"issue":"10199","key":"2013_CR2","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(19)31950-6","volume":"394","author":"KK Ray","year":"2019","unstructured":"Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019;394(10199):697\u2013708.","journal-title":"Lancet"},{"issue":"2","key":"2013_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/oxfordjournals.eurheartj.a015225","volume":"18","author":"KA Mitropoulos","year":"1997","unstructured":"Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J. 1997;18(2):235\u201341. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a015225.","journal-title":"Eur Heart J"},{"issue":"20","key":"2013_CR4","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","volume":"279","author":"RS Rosenson","year":"1998","unstructured":"Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279(20):1643\u201350. https:\/\/doi.org\/10.1001\/jama.279.20.1643.","journal-title":"JAMA"},{"issue":"5","key":"2013_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","volume":"95","author":"G O'Driscoll","year":"1997","unstructured":"O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95(5):1126\u201331. https:\/\/doi.org\/10.1161\/01.CIR.95.5.1126.","journal-title":"Circulation"},{"issue":"9","key":"2013_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839\u201344. https:\/\/doi.org\/10.1161\/01.CIR.98.9.839.","journal-title":"Circulation"},{"issue":"1","key":"2013_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.286.1.64","volume":"286","author":"MA Albert","year":"2001","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64\u201370. https:\/\/doi.org\/10.1001\/jama.286.1.64.","journal-title":"JAMA"},{"key":"2013_CR8","doi-asserted-by":"publisher","first-page":"e58567","DOI":"10.7554\/eLife.58567","volume":"9","author":"CM Schooling","year":"2020","unstructured":"Schooling CM, Zhao JV, Au Yeung SL, Leung GM. Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation. Elife. 2020;9:e58567. https:\/\/doi.org\/10.7554\/eLife.58567.","journal-title":"Elife"},{"key":"2013_CR9","doi-asserted-by":"publisher","first-page":"e57191","DOI":"10.7554\/eLife.57191","volume":"9","author":"P Carter","year":"2020","unstructured":"Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank. Elife. 2020;9:e57191. https:\/\/doi.org\/10.7554\/eLife.57191.","journal-title":"Elife"},{"issue":"7","key":"2013_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.2020.0150","volume":"323","author":"J Yarmolinsky","year":"2020","unstructured":"Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer. JAMA. 2020;323(7):646\u201355. https:\/\/doi.org\/10.1001\/jama.2020.0150.","journal-title":"JAMA"},{"issue":"1","key":"2013_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45(1):89\u2013118. https:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.095748.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9965","key":"2013_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","volume":"385","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351\u201361.","journal-title":"Lancet"},{"issue":"10","key":"2013_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jacc.2015.12.060","volume":"67","author":"P W\u00fcrtz","year":"2016","unstructured":"W\u00fcrtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. J Am Coll Cardiol. 2016;67(10):1200\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.060.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2013_CR14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","volume":"138","author":"E Sliz","year":"2018","unstructured":"Sliz E, Kettunen J, Holmes MV, Williams CO, Boachie C, Wang Q, et al. Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation. 2018;138(22):2499\u2013512. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034942.","journal-title":"Circulation"},{"issue":"12","key":"2013_CR15","doi-asserted-by":"publisher","first-page":"e3000572","DOI":"10.1371\/journal.pbio.3000572","volume":"17","author":"J Kettunen","year":"2019","unstructured":"Kettunen J, Holmes MV, Allara E, Anufrieva O, Ohukainen P, Oliver-Williams C, et al. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition. Plos Biol. 2019;17(12):e3000572. https:\/\/doi.org\/10.1371\/journal.pbio.3000572.","journal-title":"Plos Biol"},{"issue":"4","key":"2013_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/oxfordjournals.aje.a008748","volume":"143","author":"PA Sytkowski","year":"1996","unstructured":"Sytkowski PA, D'Agostino RB, Belanger A, Kannel WB. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. Am J Epidemiol. 1996;143(4):338\u201350. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a008748.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2013_CR17","doi-asserted-by":"publisher","first-page":"e033323","DOI":"10.1136\/bmjopen-2019-033323","volume":"10","author":"L Lou","year":"2020","unstructured":"Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open. 2020;10(1):e033323. https:\/\/doi.org\/10.1136\/bmjopen-2019-033323.","journal-title":"BMJ Open"},{"issue":"5","key":"2013_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.euo.2020.08.013","volume":"3","author":"M Koti","year":"2020","unstructured":"Koti M, Ingersoll MA, Gupta S, Lam CM, Li X, Kamat AM, et al. Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment. Eur Urol Oncol. 2020;3(5):622\u201330. https:\/\/doi.org\/10.1016\/j.euo.2020.08.013.","journal-title":"Eur Urol Oncol"},{"key":"2013_CR19","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. https:\/\/doi.org\/10.7554\/eLife.34408.","journal-title":"Elife"},{"issue":"4","key":"2013_CR20","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/ejhg.2014.123","volume":"23","author":"Z Ye","year":"2015","unstructured":"Ye Z, Mayer J, Ivacic L, Zhou Z, He M, Schrodi SJ, et al. Phenome-wide association studies (PheWASs) for functional variants. Eur J Hum Genet. 2015;23(4):523\u20139. https:\/\/doi.org\/10.1038\/ejhg.2014.123.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"2013_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1515\/cclm-2017-0347","volume":"56","author":"AA Arguinano","year":"2018","unstructured":"Arguinano AA, Ndiaye NC, Masson C, Visvikis-Siest S. Pleiotropy of ABO gene: correlation of rs644234 with E-selectin and lipid levels. Clin Chem Lab Med. 2018;56(5):748\u201354. https:\/\/doi.org\/10.1515\/cclm-2017-0347.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2013_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith GD, Ebrahim S. \u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1\u201322. https:\/\/doi.org\/10.1093\/ije\/dyg070.","journal-title":"Int J Epidemiol"},{"issue":"22","key":"2013_CR23","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1604304.","journal-title":"N Engl J Med"},{"issue":"7","key":"2013_CR24","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1056\/NEJMc1908496","volume":"383","author":"D Klarin","year":"2020","unstructured":"Klarin D, O'Donnell CJ, Kathiresan S. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2020;383(7):e50. https:\/\/doi.org\/10.1056\/NEJMc1908496.","journal-title":"N Engl J Med"},{"issue":"10","key":"2013_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2018.2866","volume":"3","author":"LA Lotta","year":"2018","unstructured":"Lotta LA, Stewart ID, Sharp SJ, Day FR, Burgess S, Luan J, et al. Association of genetically enhanced lipoprotein lipase-mediated lipolysis and low-density lipoprotein cholesterol-lowering alleles with risk of coronary disease and type 2 diabetes. JAMA Cardiol. 2018;3(10):957\u201366. https:\/\/doi.org\/10.1001\/jamacardio.2018.2866.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2013_CR26","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. Plos Med. 2015;12(3):e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779.","journal-title":"Plos Med"},{"key":"2013_CR27","doi-asserted-by":"crossref","unstructured":"Elsworth B, Lyon M, Alexander T, Liu Y, Matthews P, Hallett J, Bates P, Palmer T, Haberland V, Smith GD et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv. 2020.08.10.244293v1.","DOI":"10.1101\/2020.08.10.244293"},{"issue":"2","key":"2013_CR28","first-page":"10","volume":"2","author":"R Delongchamp","year":"2018","unstructured":"Delongchamp R, Faramawi MF, Feingold E, Chung D, Abouelenein S. The association between SNPs and a quantitative trait: power calculation. Eur J Environ Public Health. 2018;2(2):10.","journal-title":"Eur J Environ Public Health"},{"issue":"4","key":"2013_CR29","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1534\/genetics.117.300360","volume":"208","author":"LR Lloyd-Jones","year":"2018","unstructured":"Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of summary statistics from linear mixed model association on all-or-none traits to odds ratio. Genetics. 2018;208(4):1397\u2013408. https:\/\/doi.org\/10.1534\/genetics.117.300360.","journal-title":"Genetics"},{"issue":"2","key":"2013_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325. https:\/\/doi.org\/10.1093\/ije\/dyv080.","journal-title":"Int J Epidemiol"},{"issue":"7382","key":"2013_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219.","journal-title":"BMJ"},{"issue":"6","key":"2013_CR32","doi-asserted-by":"publisher","first-page":"e0218078","DOI":"10.1371\/journal.pone.0218078","volume":"14","author":"RW Read","year":"2019","unstructured":"Read RW, Schlauch KA, Elhanan G, Metcalf WJ, Slonim AD, Aweti R, et al. GWAS and PheWAS of red blood cell components in a Northern Nevadan cohort. Plos One. 2019;14(6):e0218078. https:\/\/doi.org\/10.1371\/journal.pone.0218078.","journal-title":"Plos One"},{"issue":"4","key":"2013_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jcpt.12690","volume":"43","author":"JY Cui","year":"2018","unstructured":"Cui JY, Zhou RR, Han S, Wang TS, Wang LQ, Xie XH. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis. J Clin Pharm Ther. 2018;43(4):556\u201370. https:\/\/doi.org\/10.1111\/jcpt.12690.","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"2013_CR34","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1111\/dom.13415","volume":"20","author":"J Ferri\u00e8res","year":"2018","unstructured":"Ferri\u00e8res J, Lautsch D, Gitt AK, De Ferrari G, Toplak H, Elisaf M, et al. Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - findings from 52 916 patients in the Dyslipidemia International Study (DYSIS). Diab Obes Metab. 2018;20(11):2670\u20134. https:\/\/doi.org\/10.1111\/dom.13415.","journal-title":"Diab Obes Metab"},{"issue":"2","key":"2013_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MED.0000000000000050","volume":"21","author":"M Mogadam","year":"2014","unstructured":"Mogadam M. Do statins increase the risk of diabetes or is it guilt by association? Curr Opin Endocrinol Diab Obes. 2014;21(2):140\u20135. https:\/\/doi.org\/10.1097\/MED.0000000000000050.","journal-title":"Curr Opin Endocrinol Diab Obes"},{"issue":"12","key":"2013_CR36","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1210\/jc.2009-1674","volume":"94","author":"B Banaszewska","year":"2009","unstructured":"Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab. 2009;94(12):4938\u201345. https:\/\/doi.org\/10.1210\/jc.2009-1674.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2013_CR37","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","volume":"49","author":"AS Dobs","year":"2000","unstructured":"Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49(9):1234\u20138. https:\/\/doi.org\/10.1053\/meta.2000.7716a.","journal-title":"Metabolism"},{"issue":"4","key":"2013_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1001\/jama.2017.8981","volume":"318","author":"SC Larsson","year":"2017","unstructured":"Larsson SC, Burgess S, Micha\u00eblsson K. Association of genetic variants related to serum calcium levels with coronary artery disease and myocardial infarction. JAMA. 2017;318(4):371\u201380. https:\/\/doi.org\/10.1001\/jama.2017.8981.","journal-title":"JAMA"},{"issue":"1","key":"2013_CR39","doi-asserted-by":"publisher","first-page":"42691","DOI":"10.1038\/srep42691","volume":"7","author":"L Xu","year":"2017","unstructured":"Xu L, Lin SL, Schooling CM. A Mendelian randomization study of the effect of calcium on coronary artery disease, myocardial infarction and their risk factors. Sci Rep. 2017;7(1):42691. https:\/\/doi.org\/10.1038\/srep42691.","journal-title":"Sci Rep"},{"key":"2013_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijcard.2018.05.051","volume":"267","author":"CM Schooling","year":"2018","unstructured":"Schooling CM, Luo S, Au Yeung SL, Thompson DJ, Karthikeyan S, Bolton TR, et al. Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: a Mendelian randomization investigation. Int J Cardiol. 2018;267:171\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.051.","journal-title":"Int J Cardiol"},{"issue":"3","key":"2013_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/ije\/dyz107","volume":"48","author":"NL Dimou","year":"2019","unstructured":"Dimou NL, Papadimitriou N, Gill D, Christakoudi S, Murphy N, Gunter MJ, et al. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48(3):807\u201316. https:\/\/doi.org\/10.1093\/ije\/dyz107.","journal-title":"Int J Epidemiol"},{"issue":"14","key":"2013_CR42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","volume":"335","author":"FM Sacks","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001\u20139. https:\/\/doi.org\/10.1056\/NEJM199610033351401.","journal-title":"N Engl J Med"},{"issue":"1","key":"2013_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S2468-1253(19)30294-8","volume":"5","author":"AJ Cornish","year":"2020","unstructured":"Cornish AJ, Law PJ, Timofeeva M, Palin K, Farrington SM, Palles C, et al. Modifiable pathways for colorectal cancer: a mendelian randomisation analysis. Lancet Gastroenterol Hepatol. 2020;5(1):55\u201362. https:\/\/doi.org\/10.1016\/S2468-1253(19)30294-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2013_CR44","doi-asserted-by":"crossref","unstructured":"Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastin in preparation for a large mortality study. Eur Heart J. 1994;15:255\u201369.","DOI":"10.1093\/oxfordjournals.eurheartj.a060485"},{"key":"2013_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.thromres.2016.08.012","volume":"148","author":"PJ Vinholt","year":"2016","unstructured":"Vinholt PJ, Hvas AM, Frederiksen H, Bathum L, J\u00f8rgensen MK, Nybo M. Platelet count is associated with cardiovascular disease, cancer and mortality: a population-based cohort study. Thromb Res. 2016;148:136\u201342. https:\/\/doi.org\/10.1016\/j.thromres.2016.08.012.","journal-title":"Thromb Res"},{"issue":"12","key":"2013_CR46","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1161\/ATVBAHA.118.311804","volume":"38","author":"D Gill","year":"2018","unstructured":"Gill D, Monori G, Georgakis MK, Tzoulaki I, Laffan M. Genetically determined platelet count and risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2018;38(12):2862\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311804.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2013_CR47","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.amjcard.2018.10.016","volume":"123","author":"S He","year":"2019","unstructured":"He S, Lei W, Li J, Yu K, Yu Y, Zhou L, et al. Relation of platelet parameters with incident cardiovascular disease (the Dongfeng-Tongji Cohort Study). Am J Cardiol. 2019;123(2):239\u201348. https:\/\/doi.org\/10.1016\/j.amjcard.2018.10.016.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2013_CR48","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/HCO.0000000000000624","volume":"34","author":"K Pafili","year":"2019","unstructured":"Pafili K, Penlioglou T, Mikhailidis DP, Papanas N. Mean platelet volume and coronary artery disease. Curr Opin Cardiol. 2019;34(4):390\u20138. https:\/\/doi.org\/10.1097\/HCO.0000000000000624.","journal-title":"Curr Opin Cardiol"},{"issue":"1","key":"2013_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/brain\/awz362","volume":"143","author":"EL Harshfield","year":"2020","unstructured":"Harshfield EL, Sims MC, Traylor M, Ouwehand WH, Markus HS. The role of haematological traits in risk of ischaemic stroke and its subtypes. Brain. 2020;143(1):210\u201321. https:\/\/doi.org\/10.1093\/brain\/awz362.","journal-title":"Brain"},{"issue":"27","key":"2013_CR50","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","volume":"39","author":"F Mach","year":"2018","unstructured":"Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehy182.","journal-title":"Eur Heart J"},{"issue":"2","key":"2013_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, et al. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diab Endocrinol. 2017;5(2):97\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(16)30396-5.","journal-title":"Lancet Diab Endocrinol"},{"issue":"5","key":"2013_CR52","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18773\/austprescr.2016.060","volume":"39","author":"MM Page","year":"2016","unstructured":"Page MM, Watts GF. PCSK9 inhibitors - mechanisms of action. Aust Prescr. 2016;39(5):164\u20137. https:\/\/doi.org\/10.18773\/austprescr.2016.060.","journal-title":"Aust Prescr"},{"issue":"13","key":"2013_CR53","doi-asserted-by":"publisher","first-page":"e008953","DOI":"10.1161\/JAHA.118.008953","volume":"7","author":"Y Handelsman","year":"2018","unstructured":"Handelsman Y, Lepor NE. PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. J Am Heart Assoc. 2018;7(13):e008953.","journal-title":"J Am Heart Assoc"},{"key":"2013_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S33664","volume":"8","author":"BAP Phan","year":"2012","unstructured":"Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327. https:\/\/doi.org\/10.2147\/VHRM.S33664.","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"2013_CR55","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"C Stancu","year":"2001","unstructured":"Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378\u201387. https:\/\/doi.org\/10.1111\/j.1582-4934.2001.tb00172.x.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2013_CR56","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1007\/s11695-017-3035-5","volume":"28","author":"HE Johansson","year":"2018","unstructured":"Johansson HE, W\u00e5hl\u00e9n A, Aldenb\u00e4ck E, Haenni A. Platelet counts and liver enzymes after gastric bypass surgery. Obes Surg. 2018;28(6):1526\u201331. https:\/\/doi.org\/10.1007\/s11695-017-3035-5.","journal-title":"Obes Surg"},{"issue":"7a","key":"2013_CR57","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1079\/PHN2005806","volume":"8","author":"TJ Cole","year":"2005","unstructured":"Cole TJ, Henry CJ. The Oxford Brookes basal metabolic rate database--a reanalysis. Public Health Nutr. 2005;8(7a):1202\u201312. https:\/\/doi.org\/10.1079\/PHN2005806.","journal-title":"Public Health Nutr"},{"issue":"10","key":"2013_CR58","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","volume":"47","author":"M Nikpay","year":"2015","unstructured":"Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121\u201330. https:\/\/doi.org\/10.1038\/ng.3396.","journal-title":"Nat Genet"},{"issue":"1","key":"2013_CR59","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1741-7015-11-57","volume":"11","author":"CM Schooling","year":"2013","unstructured":"Schooling CM, Au Yeung SL, Freeman G, Cowling BJ. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11(1):57. https:\/\/doi.org\/10.1186\/1741-7015-11-57.","journal-title":"BMC Med"},{"issue":"9976","key":"2013_CR60","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"1","key":"2013_CR61","doi-asserted-by":"publisher","first-page":"e0201196","DOI":"10.1371\/journal.pone.0201196","volume":"14","author":"HF Hope","year":"2019","unstructured":"Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. Plos One. 2019;14(1):e0201196. https:\/\/doi.org\/10.1371\/journal.pone.0201196.","journal-title":"Plos One"},{"issue":"25","key":"2013_CR62","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.017.","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"2013_CR63","doi-asserted-by":"publisher","first-page":"7345","DOI":"10.1073\/pnas.1510507113","volume":"113","author":"E Bareinboim","year":"2016","unstructured":"Bareinboim E, Pearl J. Causal inference and the data-fusion problem. Proc Natl Acad Sci USA. 2016;113(27):7345\u201352. https:\/\/doi.org\/10.1073\/pnas.1510507113.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2013_CR64","doi-asserted-by":"publisher","first-page":"m131","DOI":"10.1136\/bmj.m131","volume":"368","author":"GD Batty","year":"2020","unstructured":"Batty GD, Gale CR, Kivim\u00e4ki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020;368:m131.","journal-title":"BMJ"},{"issue":"1683","key":"2013_CR65","doi-asserted-by":"publisher","first-page":"610852","DOI":"10.3389\/fgene.2020.610852","volume":"11","author":"CM Schooling","year":"2021","unstructured":"Schooling CM, Lopez PM, Yang Z, Zhao JV, Au Yeung SL, Huang JV. Use of multivariable Mendelian randomization to address biases due to competing risk before recruitment. Front Genet. 2021;11(1683):610852. https:\/\/doi.org\/10.3389\/fgene.2020.610852.","journal-title":"Front Genet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02013-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T01:03:22Z","timestamp":1625015002000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02013-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2013"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02013-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}